781 related articles for article (PubMed ID: 12788169)
1. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
[TBL] [Abstract][Full Text] [Related]
2. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G; Pötter R; Brämswig J; Wagner W; Prott FJ; Dörffel W; Körholz D; Mann G; Rath B; Reiter A; Weissbach G; Riepenhausen M; Thiemann M; Schwarze EW
J Clin Oncol; 1999 Dec; 17(12):3736-44. PubMed ID: 10577845
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.
Dörffel W; Lüders H; Rühl U; Albrecht M; Marciniak H; Parwaresch R; Pötter R; Schellong G; Schwarze EW; Wickmann L
Klin Padiatr; 2003; 215(3):139-45. PubMed ID: 12838937
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Hodgkin's disease: treatment in the late 1990s.
Schellong G
Ann Oncol; 1998; 9 Suppl 5():S115-9. PubMed ID: 9926249
[TBL] [Abstract][Full Text] [Related]
5. Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group.
Schellong G
Baillieres Clin Haematol; 1996 Sep; 9(3):619-34. PubMed ID: 8922249
[TBL] [Abstract][Full Text] [Related]
6. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90.
Dieckmann K; Pötter R; Wagner W; Prott FJ; Hörnig-Franz I; Rath B; Schellong G
Radiother Oncol; 2002 Feb; 62(2):191-200. PubMed ID: 11937246
[TBL] [Abstract][Full Text] [Related]
7. The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group.
Schellong G
Ann Oncol; 1996; 7 Suppl 4():67-72. PubMed ID: 8836413
[TBL] [Abstract][Full Text] [Related]
8. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
[TBL] [Abstract][Full Text] [Related]
9. [Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years].
Dörffel W; Albrecht M; Lüders H; Marciniak H; Parwaresch R; Schwarze EW; Trauzeddel R; Havers W; Henze G; Janka-Schaub G; Mann G; Niemeyer C; Pötter R; Schellong G; Selle B; Treuner J; Rühl U
Klin Padiatr; 1998; 210(4):212-9. PubMed ID: 9743955
[TBL] [Abstract][Full Text] [Related]
10. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.
Loeffler M; Diehl V; Pfreundschuh M; Rühl U; Hasenclever D; Nisters-Backes H; Sieber M; Tesch H; Franklin J; Geilen W; Bartels H; Cartoni C; Dölken G; Enzian J; Fuchs R; Gassmann W; Gerhartz H; Hagen-Aukamp U; Hiller E; Hinkelbein H; Hinterberger W; Kirchner H; Koch P; Krüger B; Schwarze EW
J Clin Oncol; 1997 Jun; 15(6):2275-87. PubMed ID: 9196141
[TBL] [Abstract][Full Text] [Related]
11. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy.
Elconin JH; Roberts KB; Rizzieri DA; Vermont C; Clough RW; Kim C; Dodge RK; Prosnitz LR
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1097-105. PubMed ID: 11072168
[TBL] [Abstract][Full Text] [Related]
12. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group.
Schellong G; Brämswig JH; Hörnig-Franz I; Schwarze EW; Pötter R; Wannenmacher M
Ann Oncol; 1994; 5 Suppl 2():113-5. PubMed ID: 8204510
[TBL] [Abstract][Full Text] [Related]
13. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
14. [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82].
Schellong G; Brämswig J; Ludwig R; Gerein V; Jobke A; Jürgens H; Kabisch H; Stollmann B; Weinel P; Gadner H
Klin Padiatr; 1986; 198(3):137-46. PubMed ID: 3523020
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
16. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
17. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
[TBL] [Abstract][Full Text] [Related]
18. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293
[TBL] [Abstract][Full Text] [Related]
19. Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Oncol; 2005 Dec; 16(12):1936-40. PubMed ID: 16157620
[TBL] [Abstract][Full Text] [Related]
20. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]